vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and First Western Financial Inc (MYFW). Click either name above to swap in a different company.
First Western Financial Inc is the larger business by last-quarter revenue ($27.5M vs $21.9M, roughly 1.3× Cue Biopharma, Inc.). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 10.0%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
The Western Union Company is an American multinational financial services corporation headquartered in Denver, Colorado.
CUE vs MYFW — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $27.5M |
| Net Profit | $1.6M | — |
| Gross Margin | — | — |
| Operating Margin | 9.0% | — |
| Net Margin | 7.2% | — |
| Revenue YoY | 1292.3% | — |
| Net Profit YoY | 116.7% | — |
| EPS (diluted) | $0.05 | $0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $27.5M | ||
| Q4 25 | $21.9M | $26.7M | ||
| Q3 25 | $2.1M | $26.3M | ||
| Q2 25 | $3.0M | $24.2M | ||
| Q1 25 | $421.0K | $24.8M | ||
| Q4 24 | $1.6M | $24.3M | ||
| Q3 24 | $3.3M | $22.5M | ||
| Q2 24 | $2.7M | $22.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.6M | $3.3M | ||
| Q3 25 | $-7.4M | $3.2M | ||
| Q2 25 | $-8.5M | $2.5M | ||
| Q1 25 | $-12.3M | $4.2M | ||
| Q4 24 | — | $2.7M | ||
| Q3 24 | $-8.7M | $2.1M | ||
| Q2 24 | $-10.2M | $1.1M |
| Q1 26 | — | — | ||
| Q4 25 | 9.0% | 16.6% | ||
| Q3 25 | -353.4% | 15.1% | ||
| Q2 25 | -292.3% | 13.7% | ||
| Q1 25 | -2921.4% | 21.6% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | -264.2% | 11.9% | ||
| Q2 24 | -390.6% | 6.2% |
| Q1 26 | — | — | ||
| Q4 25 | 7.2% | 12.9% | ||
| Q3 25 | -346.6% | 12.1% | ||
| Q2 25 | -287.1% | 10.3% | ||
| Q1 25 | -2911.4% | 16.9% | ||
| Q4 24 | — | 11.3% | ||
| Q3 24 | -259.6% | 9.5% | ||
| Q2 24 | -382.7% | 4.7% |
| Q1 26 | — | $0.63 | ||
| Q4 25 | $0.05 | $0.33 | ||
| Q3 25 | $-0.07 | $0.32 | ||
| Q2 25 | $-0.09 | $0.26 | ||
| Q1 25 | $-0.17 | $0.43 | ||
| Q4 24 | — | $0.28 | ||
| Q3 24 | $-0.17 | $0.22 | ||
| Q2 24 | $-0.20 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $273.4M |
| Total Assets | $42.2M | $3.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $27.1M | — | ||
| Q3 25 | $11.7M | — | ||
| Q2 25 | $27.5M | — | ||
| Q1 25 | $13.1M | — | ||
| Q4 24 | $22.5M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $30.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — |
| Q1 26 | — | $273.4M | ||
| Q4 25 | $26.4M | $265.6M | ||
| Q3 25 | $13.2M | $261.5M | ||
| Q2 25 | $18.2M | $258.8M | ||
| Q1 25 | $6.6M | $256.6M | ||
| Q4 24 | $17.5M | $252.3M | ||
| Q3 24 | $25.4M | $248.8M | ||
| Q2 24 | $21.6M | $246.9M |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $42.2M | $3.2B | ||
| Q3 25 | $31.6M | $3.2B | ||
| Q2 25 | $40.7M | $3.0B | ||
| Q1 25 | $22.3M | $2.9B | ||
| Q4 24 | $32.2M | $2.9B | ||
| Q3 24 | $44.8M | $2.9B | ||
| Q2 24 | $42.3M | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-1.1M | $-1.8M | ||
| Q3 25 | $-9.0M | $10.0M | ||
| Q2 25 | $-3.4M | $-9.1M | ||
| Q1 25 | $-8.2M | $8.0M | ||
| Q4 24 | $-36.3M | $606.0K | ||
| Q3 24 | $-7.5M | $18.8M | ||
| Q2 24 | $-10.0M | $-11.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-5.8M | ||
| Q3 25 | — | $9.0M | ||
| Q2 25 | $-3.4M | $-9.7M | ||
| Q1 25 | $-8.3M | $7.0M | ||
| Q4 24 | $-36.4M | $-607.0K | ||
| Q3 24 | $-7.5M | $18.6M | ||
| Q2 24 | $-10.0M | $-11.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | -21.6% | ||
| Q3 25 | — | 34.1% | ||
| Q2 25 | -116.5% | -39.9% | ||
| Q1 25 | -1976.7% | 28.1% | ||
| Q4 24 | -2309.3% | -2.5% | ||
| Q3 24 | -225.7% | 82.3% | ||
| Q2 24 | -376.2% | -52.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 14.9% | ||
| Q3 25 | 0.0% | 4.1% | ||
| Q2 25 | 0.9% | 2.4% | ||
| Q1 25 | 35.6% | 4.2% | ||
| Q4 24 | 4.2% | 5.0% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.4% | 1.6% |
| Q1 26 | — | — | ||
| Q4 25 | -0.68× | -0.54× | ||
| Q3 25 | — | 3.15× | ||
| Q2 25 | — | -3.63× | ||
| Q1 25 | — | 1.91× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 8.83× | ||
| Q2 24 | — | -10.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
MYFW
| Net Interest Income | $20.9M | 76% |
| Noninterest Income | $6.7M | 24% |
